General Information of Drug Therapeutic Target (DTT) (ID: TTCEJ4F)

DTT Name G1/S-specific cyclin-E1 (CCNE1)
Synonyms G1/S-specific cyclin E; Cyclin E; CCNE
Gene Name CCNE1
DTT Type
Literature-reported target
[1]
UniProt ID
CCNE1_HUMAN
TTD ID
T10052
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MPRERRERDAKERDTMKEDGGAEFSARSRKRKANVTVFLQDPDEEMAKIDRTARDQCGSQ
PWDNNAVCADPCSLIPTPDKEDDDRVYPNSTCKPRIIAPSRGSPLPVLSWANREEVWKIM
LNKEKTYLRDQHFLEQHPLLQPKMRAILLDWLMEVCEVYKLHRETFYLAQDFFDRYMATQ
ENVVKTLLQLIGISSLFIAAKLEEIYPPKLHQFAYVTDGACSGDEILTMELMIMKALKWR
LSPLTIVSWLNVYMQVAYLNDLHEVLLPQYPQQIFIQIAELLDLCVLDVDCLEFPYGILA
ASALYHFSSSELMQKVSGYQWCDIENCVKWMVPFAMVIRETGSSKLKHFRGVADEDAHNI
QTHRDSLDLLDKARAKKAMLSEQNRASPLPSGLLTPPQSGKKQSSGPEMA
Function Essential for the control of the cell cycle at the G1/S (start) transition.
KEGG Pathway
Cell cycle (hsa04110 )
Oocyte meiosis (hsa04114 )
p53 signaling pathway (hsa04115 )
PI3K-Akt signaling pathway (hsa04151 )
Hepatitis B (hsa05161 )
Measles (hsa05162 )
Pathways in cancer (hsa05200 )
Viral carcinogenesis (hsa05203 )
MicroRNAs in cancer (hsa05206 )
Prostate cancer (hsa05215 )
Small cell lung cancer (hsa05222 )
Reactome Pathway
G0 and Early G1 (R-HSA-1538133 )
SCF(Skp2)-mediated degradation of p27/p21 (R-HSA-187577 )
DNA Damage/Telomere Stress Induced Senescence (R-HSA-2559586 )
Cyclin E associated events during G1/S transition (R-HSA-69202 )
G1/S-Specific Transcription (R-HSA-69205 )
p53-Dependent G1 DNA Damage Response (R-HSA-69563 )
E2F mediated regulation of DNA replication (R-HSA-113510 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
PD-0183812 DMWYP86 Retinoblastoma 2D02.2 Terminated [1]
------------------------------------------------------------------------------------
24 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime DMGXRSZ Discovery agent N.A. Investigative [2]
(2'Z,3'E)-5-Chloro-5'-fluoro-indirubin-3'-oxime DM6AUHR Discovery agent N.A. Investigative [2]
(2'Z,3'E)-5-Chloro-5'-hydroxy-indirubin-3'-oxime DMD7WGM Discovery agent N.A. Investigative [2]
(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime DMZ0V6G Discovery agent N.A. Investigative [2]
(2'Z,3'E)-5-Fluoro-5'-chloro-indirubin-3'-oxime DMO7RFL Discovery agent N.A. Investigative [2]
(2'Z,3'E)-5-Fluoro-5'-fluoro-indirubin-3'-oxime DMJ4ABD Discovery agent N.A. Investigative [2]
(2'Z,3'E)-5-Fluoro-5'-hydroxy-indirubin-3'-oxime DM9LQH1 Discovery agent N.A. Investigative [2]
(2'Z,3'E)-5-Fluoro-5'-methoxy-indirubin-3'-oxime DMQDH3N Discovery agent N.A. Investigative [2]
(2'Z,3'E)-5-Fluoro-5'-methyl-indirubin-3'-oxime DMAS3JC Discovery agent N.A. Investigative [2]
(2'Z,3'E)-5-Nitro-5'-chloro-indirubin-3'-oxime DMYLX0U Discovery agent N.A. Investigative [2]
(2'Z,3'E)-5-Nitro-5'-fluoro-indirubin-3'-oxime DMXZ2UC Discovery agent N.A. Investigative [2]
(2'Z,3'E)-5-Nitro-5'-hydroxy-indirubin-3'-oxime DM0S82C Discovery agent N.A. Investigative [2]
(2'Z,3'E)-5-Nitro-5'-methoxy-indirubin-3'-oxime DMLOIUK Discovery agent N.A. Investigative [2]
(2'Z,3'E)-5-Nitro-5'-methyl-indirubin-3'-oxime DM6BA5L Discovery agent N.A. Investigative [2]
2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol DM1BI65 Discovery agent N.A. Investigative [3]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione DMDO175 Discovery agent N.A. Investigative [4]
3,4-diphenyl-1H-pyrrole-2,5-dione DMPK6YT Discovery agent N.A. Investigative [4]
3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol DMJZK40 Discovery agent N.A. Investigative [3]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione DMGC7RY Discovery agent N.A. Investigative [4]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione DM3EV9N Discovery agent N.A. Investigative [4]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol DMSKJ1X Discovery agent N.A. Investigative [3]
5-nitroindirubin-3'-oxime DM4K8N2 Discovery agent N.A. Investigative [2]
aloisine A DM5U1LN Discovery agent N.A. Investigative [5]
BMS-536924 DMXJB4N Discovery agent N.A. Investigative [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 24 Investigative Drug(s)

References

1 Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
2 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
3 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
4 Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
5 Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
6 Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.